HIGHLIGHTS
- who: Massimo Lodi and colleagues from the Department of Pathology, Strasbourg University Hospital, Strasbourg, France have published the research work: STARD3: A New Biomarker in HER2-Positive Breast Cancer, in the Journal: Cancers 2023, 15, x FOR PEER REVIEW of 10/03/2022
- what: The aim of this study was to investigate the predictive value of STARD3 protein expression on NST pathological response in The authors investigated STARD3 expression on a cohort of HER2-positive breast cancers. This experiment showed that the anti-STARD3 antibody recognized a punctate cytoplasmic 7 of 22 signal typical of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.